Ophthalmology Times

NMPA approves lotilaner ophthalmic solution for demodex blepharitis in China

NMPA authorization establishes a first-in-region, mechanism-based option for Demodex blepharitis in Greater China, where ...
Business Insider

Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease Demodex blepharitis impacts approximately 25 ...
Healio

‘Mite Party’ campaign designed to educate consumers about Demodex blepharitis

Please provide your email address to receive an email when new articles are posted on . The “Mite Party” campaign is designed to raise awareness about Demodex blepharitis. Tarsus launched the campaign ...
MM&M

Tarsus Pharmaceuticals throws a Mite Party to combat demodex blepharitis

Welcome to the Mite Party. In its latest effort to raise awareness about demodex blepharitis, an eye condition that affects 25 million Americans, Tarsus Pharmaceuticals is throwing a party — a Mite ...
Yicai Global

Grand Pharma Slides Despite Getting Nod to Launch World’s First Demodex Blepharitis Eye Drug in China

(Yicai) March 23 -- Shares in Grand Pharma tumbled today despite the Chinese drugmaker being given the greenlight to take its first-in-class eye treatment for demodex blepharitis, a chronic eyelid ...
The Desert Sun

FDA-Approved Drop XDEMVY Offers Targeted Relief for Demodex Blepharitis Patients, Modern Vision Solutions Reports

Modern Vision Solutions has announced the publication of a new article, “Demodex Blepharitis Treatment in Omaha,” highlighting a significant shift in how optometrists approach the treatment of chronic ...